Comprehensive Biocompatibility Compliance Services for Medical Devices

Accelerate global market access while ensuring the highest standards of patient safety with Masuu Global Solution’s Biocompatibility Compliance Services for Medical Devices. From ISO 10993 risk assessments to complete biological evaluations, we provide end‑to‑end support that helps manufacturers meet worldwide regulatory requirements with precision and confidence.

Our experts combine scientific rigor, regulatory insight, and efficient methodologies to help you demonstrate biological safety, reduce unnecessary testing, and achieve faster regulatory approvals.

Overview

At Masuu Global Solutions, we recognize that patient safety is the foundation of every medical device. Biocompatibility evaluation is a critical component of global regulatory submissions—ensuring that device materials interact safely with the human body under intended use conditions.

With increasingly stringent standards across ISO 10993, EU MDR, and other international frameworks, manufacturers need a trusted partner who can navigate biological evaluation requirements with accuracy, clarity, and efficiency.

Our biocompatibility services are designed to:
  • Reduce the need for animal testing through risk‑based approaches
  • Optimize biological evaluations with the latest scientific methodologies
  • Support quicker and smoother approvals across global markets
  • Strengthen patient safety and long‑term device performance

Partnering with Masuu gives you access to scientific toxicologists, risk assessors, and regulatory experts dedicated to guiding your device from concept to commercialization.

Our Comprehensive Biocompatibility Services

Masuu Global Solutions offers a full suite of services to help manufacturers meet biological safety requirements across different device categories and market regions.

✔ Biological Evaluation (ISO 10993 & EU MDR)

Complete biological evaluations that incorporate device materials, design, intended patient exposure, and real‑world use. We ensure all evaluations align with:
  • ISO 10993‑1: Biological Evaluation Framework
  • EU MDR Annex I (GSPRs)
  • FDA and international biological safety expectations

✔ Gap Analysis & Regulatory Roadmap

We identify missing, outdated, or non‑compliant elements in your biological evaluation package, followed by a prioritized action plan that:
  • Addresses testing gaps
  • Minimizes redundant studies
  • Ensures full alignment with ISO 10993 & MDR requirements
  • Reduces delays during Notified Body or FDA review

✔ Toxicological Risk Assessments (TRA) for Extractables & Leachables (E&L)

A thorough toxicological evaluation of chemical compounds that may migrate from your device during use. This includes:
  • Identification of extractable/leachable chemicals
  • Quantification of substance concentrations
  • Toxicological hazard characterization
  • Exposure and margin of safety calculations
  • ISO 10993‑17‑aligned safety justifications

Our risk‑based approach ensures your device meets all chemical safety requirements while avoiding unnecessary testing.

✔ Predicate Device Strategy

We leverage data from legally marketed predicate devices to:
  • Reduce testing burden
  • Decrease time‑to‑market
  • Support comparative safety justification
  • Strengthen regulatory submissions

This strategy is especially useful under EU MDR, FDA pathways, and markets with accelerated review mechanisms.

✔ Risk Mitigation & Safety Strategy

We evaluate biological hazards based on:
  • Severity
  • Probability
  • Extent of patient exposure
Then we develop a risk‑mitigation strategy to address:
  • Material‑related hazards
  • Chemical exposures
  • Use‑related biological risks
  • Long‑term safety concerns

✔ Biocompatibility Study Design & Monitoring

Every device has unique biological evaluation needs. Masuu ensures customized study design aligned with:
  • Device materials
  • Physical and chemical characterization
  • Intended use & duration of contact
  • ISO 10993 test selection

We oversee the entire study lifecycle—from protocol development to test monitoring and final reporting—to ensure regulatory‑ready output.

✔ Safety Justifications & Analysis

We prepare scientific justifications that:
  • Explain testing decisions
  • Support alternative methods in place of animal tests
  • Provide transparent, data‑driven conclusions
  • Strengthen your submission’s biological safety narrative

These justifications are essential for EU MDR assessments, FDA submissions, and Notified Body reviews.

Biological Evaluation as per EU MDR & ISO 10993
Biological Evaluation Plan (BEP)
A BEP outlines the strategy for determining biological safety. Masuu prepares risk‑based, scientifically supported BEPs that include:
  • Biological endpoints applicable to your device
  • Material characterization strategy
  • Rationale for test selection and exclusions
  • All regulatory, scientific, and toxicological inputs
Biological Evaluation Report (BER)
Our BERs provide:
  • Comprehensive review of all test results
  • Toxicological assessment of extractables & leachables
  • Integration of chemical, biological, and clinical evidence
  • Final conclusions supporting biological safety and compliance
These reports are fully aligned with ISO 10993 standards and global submission requirements.

Why Choose Masuu for Biocompatibility Compliance?

✔ Unmatched Expertise

Specialists with deep knowledge of ISO 10993, EU MDR, FDA expectations, toxicology, and risk assessment.

✔ Tailored Strategies

Every device is unique—we customize evaluations to match material, design, and clinical use characteristics.

✔ Speed & Efficiency

We provide clear, structured, and regulator‑ready documentation to accelerate approval timelines.

✔ Patient‑Safety Driven

Our work prioritizes not only compliance, but the real‑world safety and well‑being of patients who depend on your products.

Frequently Asked Questions

Biocompatibility testing evaluates how a medical device or its materials interact with the body. It helps assess whether contact with the device could cause harmful biological effects. The type and extent of evaluation depend on factors such as the device’s materials, intended use, contact with the body, and duration of contact.

Biocompatibility is important because medical devices may come into contact with skin, tissue, blood, or other parts of the body. Evaluating biological responses helps identify potential risks associated with materials and device use. The assessment forms part of demonstrating that a device is suitable for its intended clinical application.

The biocompatibility assessment depends on factors including the materials used, the type and location of body contact, contact duration, and the device’s intended clinical use. These characteristics help determine which biological risks need to be evaluated and what testing or other evidence may be appropriate for the specific device.

Biological effects that may be evaluated include irritation, sensitization, cytotoxicity, systemic toxicity, genotoxicity, hemocompatibility, and other potential biological responses. Not every endpoint applies to every device. The appropriate evaluation depends on the device’s nature, materials, contact characteristics, and intended use.

ISO 10993 is a series of international standards addressing the biological evaluation of medical devices. It provides a framework for assessing potential biological risks associated with device materials and body contact. Applying the relevant parts of the standard helps structure a biocompatibility evaluation based on the characteristics and intended use of the device.

A biological evaluation plan describes how the biological safety of a medical device will be assessed. It considers the device’s materials, manufacturing processes, body contact, duration of exposure, and potential biological hazards. The plan helps determine whether existing evidence is sufficient or whether additional testing or evaluation is needed.

Not necessarily. The extent of biological evaluation depends on the device and its characteristics. Devices with different materials, contact types, or exposure durations may present different biological risks. Existing information, previous testing, material characterization, and scientific evidence may also contribute to the overall assessment instead of requiring every possible test.

Biocompatibility testing involves specific laboratory or other assessments used to investigate potential biological effects, while biological evaluation is the broader process of assessing biological safety. A biological evaluation can consider testing, material information, scientific literature, clinical experience, and other relevant evidence to determine whether additional assessment is necessary.

Biocompatibility documentation can include information about device materials, manufacturing processes, body contact, exposure duration, biological risks, test results, and supporting scientific evidence. A biological evaluation report can bring these elements together and explain how the available evidence supports the biological safety assessment for the intended use.

Biocompatibility should be considered during medical device development rather than only immediately before regulatory submission. Early assessment of materials, manufacturing processes, and body contact characteristics can help identify potential biological risks and determine the appropriate evaluation strategy. It should also be reassessed when relevant materials, processes, or intended uses change.

Book a Demo